The company announced an oversubscribed recent funding boost toward the preclinical development of its HHLA2 and IL18BP programs CANTON, Mass.–(BUSINESS WIRE)–April 3, 2024– Conformation-X ...
CANTON, Mass.--(BUSINESS WIRE)--Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback